Overview
- Cardinal Health reported first-quarter non-GAAP EPS of $2.55 on $64.0 billion in revenue, raised its fiscal 2026 EPS outlook to $9.65–$9.85, and its shares jumped about 17.5%.
- The company highlighted strength in its Pharmaceutical and Specialty Solutions segment, which grew 23% to $59.2 billion in revenue, and said its Solaris Health acquisition is expected to close in early November.
- Guardant Health, Glaukos, and Emergent BioSolutions each beat estimates and lifted sales guidance, with shares up roughly 29.3%, 28.7%, and 29%, respectively.
- C.H. Robinson topped adjusted EPS expectations and rallied more than 21%, while Viavi Solutions and FormFactor advanced after beats and higher guidance.
- Broader trading was mixed as the Dow rose about 200 points, with Fox up after announcing a $1.5 billion accelerated share buyback and Alphabet gaining on upbeat results.